Within hours of US Food and Drug Administration approval of Veopoz (pozelimab-bbfg) for an ultra-rare hereditary disease, Regeneron Pharmaceuticals, Inc. delivered on its recent promise that the delayed FDA approval of high-dose Eylea (aflibercept) would come sooner rather than later. Veopoz and aflibercept 8mg, which are filled and finished at the same Catalent, Inc. site, both were approved on 18 August, since the FDA’s inspections under the pozelimab biologics license application (BLA) apparently cleared up the agency’s lingering questions about the contract manufacturer.
UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals
Products Produced At Same Catalent Site
Veopoz (pozelimab) approval showed the FDA was reassured that Regeneron’s contract manufacturer is ready to supply high-dose Eylea, a key product for the company as competition picks up.
More from New Products
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.